Takotsubo syndrome outcomes predicted by thyroid hormone signature: insights from cluster analysis of a multicentre registry
- PMID: 38502972
- PMCID: PMC10963195
- DOI: 10.1016/j.ebiom.2024.105063
Takotsubo syndrome outcomes predicted by thyroid hormone signature: insights from cluster analysis of a multicentre registry
Abstract
Background: Recently, abnormal thyroid function was shown to be common in patients with Takotsubo syndrome (TTS), being classified into "endocrine-type" and "stress-type" responses. The aim of this study was to investigate the association between thyroid homeostasis and TTS in a larger international registry.
Methods: In total 288 patients with TTS were enrolled through the GEIST multicentre registry from Germany, Italy and Spain. Thyrotropin (TSH), free T4 (FT4) and free T3 (FT3) concentrations were analysed at admission. Data were collected both retrospectively and prospectively from 2017 onwards. Primary endpoints included in-hospital and all-cause fatality, determined by cluster analysis using an unsupervised machine learning algorithm (k-medoids).
Findings: Three clusters were identified, classifying TTS with low (TSLT), high (TSHT) and normal (TSNT) thyroid output, based on TSH and FT4 levels in relation to the median thyroid's secretory capacity (SPINA-GT). Although TSH and FT4 concentrations were similar among survivors and non-survivors, these clusters were significantly associated with patient outcomes. In the longitudinal Kaplan-Meier analysis including in- and out-of-hospital survival, the prognosis related to concentrations of TSH, FT4, and FT3 as well as SPINA-GT, deiodinase activity (SPINA-GD) and clusters. Patients in the TSHT cluster and with cardiogenic shock had a lower initial left ventricular ejection fraction (LVEF).
Interpretation: This study suggests that thyroid hormones may impact the evolution and prognosis of TTS. The findings indicate that thyroid-derived biomarkers may help identify high-risk patients and pave the way for novel personalized and preventive therapeutic options.
Funding: This research was not funded by any public, commercial, or not-for-profit agencies.
Keywords: Stress cardiomyopathy; Takotsubo syndrome; Thyroid; Thyrotoxicosis.
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of interests JWD received funding and personal fees from Novo Nordisk, VitalAire, Abbott, Medtronic, Oviva, Egetis Therapeutics, myhomecare, aidhere, Ascensia Diabetes Care, Sanofi-Henning, Hexal AG, Bristol-Myers Squibb, and Pfizer, and is the co-owner of the intellectual property rights for the patent “System and Method for Deriving Parameters for Homeostatic Feedback Control of an Individual” (Singapore Institute for Clinical Sciences, Biomedical Sciences Institutes, Application Number 201208940-5, WIPO number WO/2014/088516). IE received funding from Else-Kröner-Fresenius Foundation (No. 2022_EKES.48) and Innovationforum (No. IF-034-22). All other authors declare no conflict of interest.
Figures
References
-
- Templin C., Ghadri J.R., Diekmann J., et al. Clinical features and outcomes of takotsubo (stress) cardiomyopathy. N Engl J Med. 2015;373:929–938. - PubMed
-
- El-Battrawy I., Lang S., Ansari U., et al. Impact of concomitant atrial fibrillation on the prognosis of Takotsubo cardiomyopathy. Europace. 2016;19(8):1288–1292. - PubMed
-
- El-Battrawy I., Lang S., Ansari U., et al. Prevalence of malignant arrhythmia and sudden cardiac death in takotsubo syndrome and its management. Europace. 2018;20:843–850. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
